Current Trends and Future Directions in Antimicrobial Resistance and Novel Drug Strategies

Khuspe Pankaj¹*, Phade Swapnil², Mane Dipali³, Gaikwad Vinay⁴, Madhare Trushali⁵,

Kashid Pooja⁶, Vyavahare Ritesh⁷

¹Associate Professor, Shriram Shikshan Sansthas College of Pharmacy, Paniv - 413113.

²Principal, Shriram Shikshan Sansthas College of Pharmacy, Paniv - 413113.

³Associate Professor, Shriram Shikshan Sansthas College of Pharmacy, Paniv - 413113.

⁴Head of Department, College of Pharmacy (Poly.), Akluj - 413101.

⁵Associate Professor, Navashyadri Institute of Pharmacy, Pune - 412213.

⁶Associate Professor, Navashyadri Institute of Pharmacy, Pune - 412213.

⁷Assistant Professor, SVERIs College of Pharmacy, Pandharpur, Solapur, Maharashtra - 413304.

*Corresponding Author E-mail: Khuspepankaj@gmail.com

ABSTRACT:

A major concern to global health, antimicrobial resistance (AMR) reduces the effectiveness of antibiotics and other antimicrobial medicines, increasing treatment failures and mortality rates. The misuse of antibiotics in agriculture and healthcare, poor sanitation, and the slow development of novel antimicrobial medicines are some of the reasons contributing to the fast evolution of resistant microorganisms. This article looks at the main processes that lead to antimicrobial resistance, such as biofilm formation, horizontal gene transfer, and genetic changes. It also looks at cutting-edge treatment strategies like bacteriophage therapy, combination medicines, and antimicrobial peptides (AMPs) that try to stop AMR. While phage therapy uses bacteriophages to specifically target and kill bacteria, AMPs offer a special mode of action that targets microbial membranes. Additionally, combination medicines are becoming more popular, especially those that combine conventional antibiotics with non-antibiotic adjuvants or resistance-modifying compounds to increase the effectiveness of existing medications and postpone the establishment of resistance. This article provides a thorough examination of these methods, highlighting potential tactics and new lines of inquiry that may be able to lessen the AMR epidemic and protect public health. Mitigating AMR in the future will necessitate a multipronged strategy that includes both innovative treatments and calculated policy changes to manage resistance.

KEYWORDS: Antimicrobial resistance, Novel therapeutics, Antimicrobial peptides, Phage therapy, Combination therapies.

1. INTRODUCTION:

Since it undermines the effectiveness of currently available therapies and raises rates of morbidity and mortality, antimicrobial resistance (AMR) has become a serious and expanding global public health concern. AMR reduces the efficacy of therapies for a wide range of infectious disorders because microorganisms, such as bacteria, fungi, parasites, and viruses, can withstand the effects of medications intended to eradicate them. This resistance raises the likelihood of disease transmission, prolongs illnesses, and raises healthcare expenses. AMR is accelerated in large part by the pervasive overuse and abuse of antibiotics. Antibiotics are commonly recommended in clinical settings for viral diseases that they are ineffective against, such influenza or colds. Such improper use encourages the survival and spread of resistant types of bacteria by applying selective pressure. Furthermore, the frequent use of antibiotics to boost cattle development in agricultural techniques produces a reservoir of resistant genes that can infect human populations through food and the environment. This issue is made worse by inadequate infection control practices and poor sanitation, which allow resistant germs to spread throughout communities. The situation is made worse by the drop in the discovery of new antibiotics. The development of novel antimicrobials has stalled as a result of pharmaceutical research's change in emphasis over the last few decades to chronic illnesses. There is a startling lack of effective medications to treat resistant diseases because creating new antibiotics is a difficult, expensive, and time-consuming process with few financial incentives^1-3.

The effects of AMR on healthcare systems are profound and extensive. Longer hospital stays, more diagnostic testing, and higher medical expenses are all consequences of resistant infections, which frequently need for more involved, hazardous, or expensive therapies. Additionally, AMR reduces the efficacy of medical treatments like organ transplants, cancer chemotherapy, and operations that depend on preventative antibiotics. These treatments involve a higher risk in the absence of efficient antibiotics, which calls into question the fundamentals of contemporary medicine. Improved antibiotic stewardship, quick diagnostics, and innovative therapeutic approaches must all be used in a multidimensional strategy to combat AMR. In order to guarantee thorough surveillance and monitoring, antibiotic use control, and ongoing investment in research and development, it also calls for international cooperation^4-5.

Figure No.1 -AMR's primary drivers

2. Mechanisms of Antimicrobial Resistance:

The effectiveness of therapeutic treatments is compromised by antimicrobial resistance (AMR), which is caused by a number of intricate mechanisms that allow bacteria to resist the actions of antimicrobial medicines. These mechanisms are adaptive reactions to the selective pressures imposed by antimicrobial treatments rather than solitary occurrences. Here, we look at the three main ways that bacteria become resistant: biofilm development, horizontal gene transfer, and genetic alterations^1,6.

2.1 Genetic Mutations:

Genetic mutation is one of the most basic processes of resistance development. Bacterial DNA mutations happen on their own and can give rise to drug-resistant characteristics that help germs avoid the effects of antibiotics. These changes may decrease drug affinity, change the antibiotics' target locations, or boost efflux activity, which removes antibiotics from bacterial cells. Antibiotics may become ineffective due to mutations in genes that code for ribosomal proteins or enzymes involved in the manufacture of cell walls. These alterations may be transmitted down to succeeding generations when bacteria multiply, creating resistant populations in the bacterial community⁷.

2.2 Horizontal Gene Transfer (HGT):

Another important mechanism by which bacteria develop resistance is horizontal gene transfer. HGT permits the transmission of resistance genes across bacterial cells, even between distinct species, in contrast to mutations that take place within a single bacterial cell. Three main mechanisms underlie this process: transduction (transfer facilitated by bacteriophages), transformation (uptake of free DNA from the environment), and conjugation (transfer through direct cell-to-cell contact). HGT is a powerful mechanism for the transmission of AMR because it allows bacteria to quickly acquire and transfer resistance characteristics among microbial populations^8-9.

2.3 Biofilm Formation:

A physical barrier known as biofilms helps bacteria survive and develop resistance. Bacteria group together in biofilms, which are protected from outside dangers like antimicrobial agents by an extracellular matrix that the bacteria build on their own. Antibiotics cannot penetrate biofilms due to their densely packed structure, which permits bacteria in the inner layers to persist and grow. Furthermore, biofilms promote the development and maintenance of resistance traits by establishing a localised environment that facilitates genetic exchange and mutations. Because biofilms can develop on medical equipment and cause chronic infections that are challenging to treat, biofilm-associated resistance is especially problematic in healthcare settings. When taken as a whole, these processes highlight how intricate and adaptable AMR is, with bacteria constantly developing new ways to avoid antibiotics. A comprehensive strategy that incorporates infection control, good antibiotic stewardship, and the creation of novel therapeutic modalities is needed to address these resistance mechanisms¹⁰.

Table 1 - Main mechanisms of AMR associated with different antibiotic classes^1-11.

Antibiotic Class	Resistance Mechanism	Description	Example Pathogens
β-lactams	β-lactamase enzyme production	Bacteria produce enzymes (β-lactamases) that break down β-lactam antibiotics, make them ineffective.	Staphylococcus aureus, Escherichia coli
Aminoglycosides	Target site modification	Mutations or enzymatic modifications alter ribosomal binding sites, reducing antibiotic binding and efficacy.	Pseudomonas aeruginosa, Enterococcus spp.
Fluoroquinolones	Increased efflux pump activity	Bacteria increase the activity of efflux pumps to expel the antibiotic out of the cell, decreasing intracellular concentration.	Escherichia coli, Neisseria gonorrhoeae
Tetracyclines	Ribosomal protection proteins	Proteins protect ribosomes from tetracycline binding, preventing its action on bacterial protein synthesis.	Acinetobacterbaumannii, Streptococcus spp.
Macrolides	Altered cell membrane permeability	Changes in cell membrane reduce drug uptake, or methylation of ribosomal RNA prevents antibiotic binding.	Streptococcus pneumoniae, Helicobacter pylori
Sulfonamides	Alternative metabolic pathways	Bacteria bypass metabolic steps targeted by the antibiotic through alternative enzymatic pathways.	Escherichia coli, Klebsiellapneumoniae
Carbapenems	Carbapenemase enzyme production	Bacteria produce carbapenemase enzymes that hydrolyze carbapenem antibiotics, a last-resort drug class.	Klebsiellapneumoniae, Acinetobacterbaumannii
Glycopeptides (e.g., Vancomycin)	Cell wall modification	Bacteria alter cell wall precursors, reducing the binding affinity of the antibiotic.	Enterococcus faecium, Staphylococcus aureus
Polymyxins (e.g., Colistin)	Lipid A modification in outer membrane	Modifications in lipid A structure of the bacterial outer membrane reduce polymyxin binding.	Pseudomonas aeruginosa, Acinetobacterbaumannii
Oxazolidinones (e.g., Linezolid)	23S rRNA mutation	Mutations in 23S rRNA of the ribosome hinder drug binding, preventing inhibition of protein synthesis.	Staphylococcus aureus, Enterococcus spp.
Chloramphenicol	Chloramphenicol acetyltransferase (CAT) enzyme production	CAT enzyme inactivates chloramphenicol by acetylating the drug, preventing it from binding to ribosomes.	Salmonella spp., Haemophilusinfluenzae
Quinolones	DNA gyrase/topoisomerase mutations	Mutations in DNA gyrase or topoisomerase enzymes hinder quinolone binding, allowing DNA replication to proceed.	Escherichia coli, Mycobacterium tuberculosis
Rifamycins (e.g., Rifampicin)	RNA polymerase mutation	Mutations in RNA polymerase reduce rifamycin binding, allowing bacterial RNA synthesis to continue.	Mycobacterium tuberculosis, Neisseria meningitidis
Folate synthesis inhibitors	Altered dihydropteroate synthase enzyme	Mutation in enzyme dihydropteroate synthase lowers binding affinity for drugs like sulfonamides, inhibiting their effect.	Escherichia coli, Plasmodium falciparum
Streptogramins	Enzymatic inactivation	Bacterial enzymes modify the structure of streptogramins, reducing their efficacy in inhibiting protein synthesis.	Enterococcus faecium, Staphylococcus aureus

3. Novel Therapeutic Approaches:

The need to investigate novel therapeutic approaches that can get beyond the drawbacks of conventional antibiotics is urgent given that antimicrobial resistance (AMR) is becoming a worldwide health emergency. Here, we look at three promising strategies: combination medicines, phage therapy, and antimicrobial peptides (AMPs). Through distinct processes, each of these approaches targets resistant microorganisms in an effort to mitigate or circumvent the danger of resistance^11-12.

3.1 Antimicrobial Peptides (AMPs):

Naturally occurring short peptides known as antimicrobial peptides (AMPs) have broad-spectrum antimicrobial activity against a variety of pathogens, including as bacteria, viruses, and fungi. Through electrostatic interactions with the negatively charged microbial cell surfaces, AMPs mostly damage microbial cell membranes, causing cell lysis and death. It is difficult for infections to alter basic membrane structures without endangering their survival, therefore the quick and physical character of this activity lowers the chance of resistance development. Additionally, AMPs have immune-modulating qualities, which increases their potential as a treatment. Optimising AMP stability, reducing toxicity to human cells, and creating delivery mechanisms that increase AMP bioavailability are the main goals of recent research^14-15.

3.2 Phage Therapy:

Phage therapy treats bacterial illnesses by using bacteriophages, which are viruses that attack and destroy bacterial cells. After attaching to particular bacterial receptors, bacteriophages inject their genetic material and use the bacterial machinery to multiply, which leads to the destruction of bacterial cells. Bacteriophages are very particular to their bacterial hosts, which minimises off-target effects and preserves beneficial microbiota, in contrast to antibiotics. The capacity of phages to co-evolve with bacteria, possibly surpassing the emergence of resistance, is a special benefit. Currently, phage treatment is being researched to treat illnesses that are resistant to many drugs, particularly when antibiotics have not worked. Regulatory permissions, patient-specific phage selection, and guaranteeing uniform efficacy among bacterial strains are still obstacles, nevertheless^16-17.

3.3 Combination Therapies:

Combination therapies cure infections by using two or more medications or agents at the same time. Combining antibiotics with adjuvants, agents that change resistance, or other substances that increase antimicrobial action can be one way to do this. By lowering the necessary dosage of each medication and lowering toxicity while increasing efficacy, combination medicines can function in concert. Combination therapy are an efficient technique to get over bacterial defences by focussing on several resistance mechanisms or pathways. For example, β-lactamase inhibitors and β-lactam antibiotics work together to combat enzyme-mediated resistance. Another tactic is to combine antibiotics with non-antibiotic substances, such as efflux pump inhibitors, which enhance the drug's efficacy by blocking bacterial resistance routes¹⁸.

4. Future Directions in AMR Management:

Effectively combating antimicrobial resistance (AMR) necessitates a multifaceted approach that includes developments in drug discovery, prudent management of currently available antimicrobials, and extensive national and international regulatory frameworks. To stop the spread of AMR and guarantee the long-term sustainability of antimicrobial treatments, these three pillars research and development, legislative reform, and international cooperation are crucial^{1, 5}.

Table no: 2 Examples of effective combination therapies^18-20

Drug Combination	Target Pathogen (s)	Mechanism of Action	Benefits	Clinical/Experimental Status
β-lactam + β-lactamase inhibitor	Escherichia coli, Klebsiellapneumoniae	The β-lactamase inhibitor (e.g., clavulanic acid, tazobactam) blocks bacterial β-lactamase enzymes, allowing β-lactam antibiotics (e.g., amoxicillin) to effectively bind and inhibit bacterial cell wall synthesis.	Restores effectiveness of β-lactam antibiotics, particularly against β-lactamase-producing bacteria.	Widely used clinically; numerous combinations FDA-approved
Aminoglycoside + Cell wall synthesis inhibitor	Staphylococcus aureus, Enterococcus spp.	The cell wall synthesis inhibitor (e.g., vancomycin) disrupts the bacterial cell wall, enhancing aminoglycoside (e.g., gentamicin) penetration and uptake, leads to increased protein synthesis inhibition.	Synergistic effect allows for lower doses, reducing aminoglycoside-associated nephrotoxicity.	Used clinically, especially for severe infections like endocarditis
Fluoroquinolone + Efflux pump inhibitor	Pseudomonas aeruginosa, Klebsiellapneumonia	The efflux pump inhibitor (e.g., phenylalanine-arginine β-naphthylamide, PAβN) prevents bacterial efflux of fluoroquinolones (e.g., ciprofloxacin), allowing higher intracellular concentrations of the antibiotic.	Overcomes resistance associated with efflux pumps, improving treatment efficacy.	Primarily experimental; some preclinical studies ongoing
Tetracycline + Metal chelating agent	Acinetobacterbaumannii, Pseudomonas aeruginosa	The metal chelating agent (e.g., EDTA) binds essential metal ions, disrupting bacterial metabolism and enhancing tetracycline action.	Dual mechanism of disrupting metabolism and protein synthesis; targets drug-resistant strains.	Experimental; used in some severe cases of multi-drug resistance
Phage + Antibiotic	Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus (MRSA)	Phages selectively lyse bacterial cells while the antibiotic (e.g., gentamicin) exerts its typical action, potentially reducing bacterial density more effectively.	High specificity with minimal impact on human microbiota; adaptable to bacterial evolution.	Experimental; promising results in compassionate use cases and clinical trials
Polymyxin + Outer membrane permeabilizer	Klebsiellapneumoniae, Escherichia coli	The permeabilizer (e.g., CCCP) disrupts bacterial outer membrane integrity, allowing polymyxin to penetrate and damage inner cellular structures.	Enhances polymyxin action at lower doses, reducing toxicity.	Experimental; research ongoing for severe Gram-negative infections
Oxazolidinone (e.g., Linezolid) + Rifampicin	Staphylococcus aureus, Mycobacterium tuberculosis	Linezolid inhibits bacterial protein synthesis, while rifampicin disrupts RNA synthesis; combination prevents rapid resistance development.	Dual inhibition reduces risk of resistance, effective against persistent infections.	Clinically tested for specific infections, including resistant TB
Macrolide (e.g., Azithromycin) + Anti-inflammatory agent	Haemophilusinfluenzae, Streptococcus pneumonia	Macrolide antibiotic inhibits bacterial protein synthesis, while anti-inflammatory agent (e.g., ibuprofen) reduces inflammation associated with infection.	Combination enhances host response, minimizes tissue damage, improves patient outcomes.	Experimental in clinical trials for respiratory infections
Carbapenem + β-lactamase inhibitor	Carbapenem-resistant Enterobacteriaceae	The β-lactamase inhibitor (e.g., vaborbactam) inhibits carbapenemase enzymes, restoring carbapenem’s action on bacterial cell walls.	Extends carbapenem efficacy against carbapenemase-producing bacteria, providing an option for last-resort cases.	Recently approved for clinical use in specific cases

4.1 Research and Development:

To increase our therapeutic arsenal against infections that are resistant, research and development investments are essential. Since resistance outpaces the development of new medications, funding programs focused on the discovery of new antibiotics are essential. Novel therapeutic compounds that target microbial membranes and exhibit reduced susceptibilities to the development of resistance, such as antimicrobial peptides (AMPs), are encouraging directions. Furthermore, the development of bacteriophage (phage) therapy—which uses viruses that selectively target and destroy bacterial cells—may offer a flexible remedy, especially in the case of germs that are resistant to many drugs. Research funding and regulatory backing must continue if these treatments are to move from the experimental stage to broad clinical use^21-22.

4.2 Policy and Regulations:

To prevent the abuse and overuse of antibiotics in medicine, veterinary care, and agriculture, effective laws and regulations are essential. Important measures include limiting the use of antibiotics for livestock growth enhancement and establishing stringent rules for the prescribing of antibiotics in therapeutic settings. Penalties for overprescription and misuse may serve as deterrents, and the implementation of monitoring systems can assist in tracking patterns of antibiotic usage and resistance. The implementation of stewardship programs in hospitals can offer instruction on the safe use of antibiotics, and regulatory agencies must collaborate with healthcare facilities to guarantee compliance^23-27.

4.3 Global Collaboration:

Since AMR is a worldwide problem that cuts beyond national boundaries, international cooperation is crucial to its efficient management. Through data-sharing programs and coordinated monitoring efforts, like the Global Antimicrobial Resistance Monitoring System (GLASS) of the World Health Organisation, nations may efficiently respond to new threats and track AMR trends in real time. This international strategy encourages nations to submit resistance statistics, implement standardised testing procedures, and exchange best practices for effective therapies. Collaborations among governmental organisations, academic institutions, and the commercial sector can further spur innovation and make it possible to deploy AMR countermeasures on a broad scale. Global cooperation can go beyond surveillance to include resource sharing for impoverished nations, which frequently lack the infrastructure necessary for effective AMR monitoring and intervention. Technical aid, finance support, and capacity-building initiatives are required to guarantee a thorough and just approach to AMR management globally. An integrated strategy that incorporates international collaboration, legislative action, and scientific innovation is the way of the future for managing AMR. It is possible to halt the development of AMR and create resilient solutions that safeguard global health for future generations if persistent efforts are made in each of these areas^28-34.

5. CONCLUSION:

The serious danger that antimicrobial resistance (AMR) poses to contemporary healthcare emphasises the urgent need for coordinated action. AMR threatens to make existing treatments ineffective, exacerbate global health issues, and increase mortality rates if prompt action is not taken. Antimicrobial peptides (AMPs), phage therapy, and combination treatments are examples of novel therapeutic approaches that have great potential for combating resistant bacteria. With their distinct processes, these cutting-edge strategies provide alternate avenues for managing AMR and lessen reliance on conventional antibiotics. The implementation of these treatments needs to be incorporated into a well-organised system of laws and regulations. Effective laws that limit the abuse of antibiotics in agriculture and healthcare, as well as monitoring programs that keep an eye on prescriptions and usage, are essential to preventing the emergence of resistance. Furthermore, implementing good antimicrobial stewardship requires national and local efforts to regulate antibiotic use. International cooperation is still a crucial component of the AMR response. Global data-sharing networks, like the Global Antimicrobial Resistance Surveillance System (GLASS) of the World Health Organisation, enable timely surveillance, share research discoveries, and provide a cohesive, cross-border approach to combating AMR. By providing technical assistance, resources, and infrastructure for AMR monitoring to developing nations, this global front is strengthened and an inclusive and coordinated strategy to AMR combat is ensured. Effective AMR management is built on a multifaceted strategy that combines cutting-edge treatments, strong legislation, and international collaborations. There is potential to lessen the effects of AMR and ensure that antimicrobial treatments continue to be effective for future generations with consistent dedication across these domains.

6. REFERENCES:

1. Salam MA, Al-Amin MY, Salam MT, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023; 11(13): 1946. doi:10.3390/healthcare11131946

2. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018; 11: 1645-1658.  doi:10.2147/IDR.S173867

3. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, et al. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Clinical Laboratory Analysis. 2022; 36(9). https://doi.org/10.1002/jcla.24655

4. Suresh A. Marnoor. A Review on Antimicrobial Resistance and Role of Pharmacist in tackling this Global Threat. Res. J. Pharm. Dosage Form. & Tech. 2017; 9(4): 143-146.

5. Ahmed SK, Hussein S, Qurbani K, et al. antimicrobial resistance: Impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health. 2024; 2: 100081. https://doi.org/10.1016/j.glmedi.2024.100081

6. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018; 4(3): 482-501. Published 2018 Jun 26. doi:10.3934/microbiol.2018.3.482

7. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals (Basel). 2023; 16(11): 1615. Published 2023 Nov 15. doi:10.3390/ph16111615

8. Michaelis C, Grohmann E. Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms. Antibiotics (Basel). 2023; 12(2): 328. Published 2023 Feb 4. doi:10.3390/antibiotics12020328

9. Tao S, Chen H, Li N, Wang T, Liang W. The Spread of Antibiotic Resistance Genes In Vivo Model. Can J Infect Dis Med Microbiol. 2022; 2022: 3348695. Published 2022 Jul 18. doi:10.1155/2022/3348695

10. Hisham A. Abbas, Fathy M. Serry, Eman M. EL-Masry. Biofilms: The Microbial Castle of Resistance. Research J. Pharm. and Tech. 6(1): Jan. 2013; Page 01-03.

11. Devi NS, Mythili R, Cherian T, et al. Overview of antimicrobial resistance and mechanisms: The relative status of the past and current. The Microbe. 2024; 3: 100083. https://doi.org/10.1016/j.microb.2024.100083

12. Murugaiyan J, Kumar PA, Rao GS, et al. Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics (Basel). 2022; 11(2): 200. Published 2022 Feb 4. doi:10.3390/antibiotics11020200

13. Alaoui Mdarhri H, Benmessaoud R, Yacoubi H, et al. Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine. Antibiotics (Basel). 2022; 11(12): 1826. Published 2022 Dec 16. doi:10.3390/antibiotics11121826.

14. Huan Y, Kong Q, Mou H, Yi H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11:582779. Published 2020 Oct 16. doi:10.3389/fmicb.2020.582779

15. Zhang Q, Yan Z, Meng Y, et al. antimicrobial peptides: mechanism of action, activity and clinical potential. Military Med Res. 2021; 8(1). https://doi.org/10.1186/s40779-021-00343-2

16. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017; 8(3): 162-173. doi:10.4292/wjgpt. v8.i3.162

17. Hisham A. Abbas, Mona A. El-Sayed, Laila M. Al-Kadi, Amany I. Gad. Diabetic foot infections in Zagazig University Hospital: bacterial etiology, antimicrobial resistance and biofilm formation. Research J. Pharm. and Tech. 2014; 7(7): 783-788.

18. G. Sneha Bokadia, P. Gopinath. Bacteriophage in Human Body A –Systematic Review. Research J. Pharm. and Tech. 2017; 10(4): 1204-1208.

19. Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013; 31(3): 177-184. doi: 10.1016/j.tibtech.2012.12.006

20. Sullivan GJ, Delgado NN, Maharjan R, Cain AK. How antibiotics work together: molecular mechanisms behind combination therapy. Current Opinion in Microbiology. 2020; 57: 31-40. DOI: 10.1016/j.mib.2020.05.012

21. Iskandar K, Murugaiyan J, Hammoudi Halat D, Hage SE, Chibabhai V, Adukkadukkam S, Roques C, Molinier L, Salameh P, Van Dongen M. Antibiotic Discovery and Resistance: The Chase and the Race. Antibiotics. 2022; 11(2): 182. https://doi.org/10.3390/antibiotics11020182

22. Gholap AD, Khuspe PR, Pardeshi SR, et al. Achieving Optimal Health with Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon. Advanced Therapeutics. 2024, 2400169, https://doi.org/10.1002/adtp.202400169

23. Kasimanickam V, et. al. Antibiotics Use in Food Animal Production: Escalation of Antimicrobial Resistance: Where Are We Now in Combating AMR? Med Sci (Basel). 2021; 9(1): 14. doi:10.3390/medsci9010014

24. Sreeja. M.K, Gowrishankar N.L, Adisha. S, Divya. K.C. Antibiotic Resistance-Reasons and the Most Common Resistant Pathogens – A Review. Research J. Pharm. and Tech. 2017; 10(6): 1886-1890.

25. Willemsen, A., Reid, S. & Assefa, Y. A review of national action plans on antimicrobial resistance: strengths and weaknesses. Antimicrob Resist Infect Control. 2022, 11, 90. https://doi.org/10.1186/s13756-022-01130-x

26. Wernli D, Harbarth S, Levrat N, Pittet D. A 'whole of United Nations approach' to tackle antimicrobial resistance? A mapping of the mandate and activities of international organisations. BMJ Glob Health. 2022; 7(5): e008181. doi:10.1136/bmjgh-2021-008181

27. Hisham A. Abbas, Mona A. El-Saysed, Amira M. Ganiny, Azza Abdel Fattah. Antimicrobial Resistance Patterns of Proteus mirabilis isolates from Urinary tract, burn wound and Diabetic foot Infections. Research J. Pharm. and Tech. 2018; 11(1): 249-252.

28. Freshinta Jellia Wibisono, Dyah Ayu Widiasih, Hung Nguyen-Viet. Multidrug Resistance of Escherichia coli in cats and the Level of Understanding of Cat Owners on Antimicrobial Resistance. Research Journal of Pharmacy and Technology. 2024; 17(8): 3855-2.

29. Yash Bhardwaj, Sanket N. Kadam. Antibiotic Resistance: A Growing Threat to Public Health. Research Journal of Pharmacy and Technology. 2024; 17(7): 3473-9.

30. Sumarlin, Syamsidar Gaffar, Adriyana Edward. Exploring the Hidden Biotechnological Treasure of Bacterial Symbionts in Xestospongia sp. from Derawan Island: A Study on Antimicrobial and Enzyme-Producing Bacteria. Research Journal of Pharmacy and Technology. 2024; 17(6): 2795-3.

31. Mohamed Ramadan, Mohammed El-mowafy, Iman Abdelmegeed, Rasha Barwa. Comparative Studies on Clinical Isolates of Hypervirulent and Classical Klebsiella pneumoniae. Research Journal of Pharmacy and Technology. 2023; 16(6): 2747-3.

32. Pradeep AN, Ramasamy S, VeniEmilda JK, VinodKumar CS. Reassessing the forgotten cure: Efficacy of bacteriophage as a therapeutic agent against MRSA in diabetic rats. Research Journal of Pharmacy and Technology 2023; 16(6):2675-2.

33. Sneha K. S., Srikant Natarajan, Karen Boaz, John Ramapuram, Shrikala Baliga, Nidhi Manaktala, Nunna Sai Chitra. Candida profile in HIV-Positive children needs a Dynamic clinical appraisal: A microbiological Study. Research Journal of Pharmacy and Technology. 2023; 16(1): 423-8.

34. Suhad Yassein Abed, Ali Haider Alsakini, Khetam Habeeb Rasool, Sundus Qasim Mohammed, Sadeq Abdulridha Gatea Kaabi. Formulation of a Novel Phage Cocktail against Vibrio cholerae O1. Research Journal of Pharmacy and Technology. 2022; 15(6): 2605-8.

Received on 11.11.2024      Revised on 04.03.2025

Accepted on 15.05.2025 Published on 10.07.2025

Available online from July 17, 2025

Asian J. Pharm. Res. 2025; 15(3):321-326.

DOI: 10.52711/2231-5691.2025.00050

©Asian Pharma Press All Right Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.